Welcome to the Servier Cardiology page!
Cardiovascular diseases are the leading cause of mortality in the world. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired renowned expertise. Developing innovative drugs for patients suffering from cardiovascular diseases is part of Servier’s original vocation1. Servier is the 4th leading company in the field of cardiology.2.** Cardiovascular diseases are the leading cause of mortality in the world. Developing innovative drugs for patients suffering from cardiovascular diseases is part of Servier’s original vocation*.
CHRONIC CORONARY SYNDROME
The 2019 ESC guidelines for the diagnosis and management of Chronic Coronary Syndrome (CCS) acknowledge that cardiac ischemia has different facets and that the treatment of patients with the chronic coronary syndrome should be adapted to each patients' characteristics and preferences3. Ischemic heart disease being the first cause of death worldwide4, adequate management of patients is essential to curb the progression to more severe heart diseases, such as heart failure. Servier offers several solutions for these symptomatic patients with chronic coronary syndrome.
Heart Failure is considered a global pandemic. A recent study confirms that Heart failure affects over 26 million people worldwide and the prevalence will increase with the aging population.
Despite the substantial advancements in therapies morbidity and mortality are still high and quality of life continues to be poor for these Heart failure patients.5 Adherence to medication and optimization of standard care is a continued need in managing Heart Failure patients to reduce symptoms, hospitalization, and death.6
The Servier Heart Failure Franchise provides a solution in the management of all Heart failure patients. ESC 2021 guidelines outline the need to up titrate to higher dose Bblocker, ACEI, and control Heart Rate below 70bpm in order to reduce symptoms, hospitalization, and death. Servier provides the trilogy of life in managing newly diagnosed Heart failure patients or Heart Failure patients already treated with a Bblocker.7
*. www. servier.com
**. IQVA, Analytics Link – MAT Q2 2021
3. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
5. Gianluigi Savarese, Global Heart Failure Burden of Heart Failure. Card Fail Rev. 2017 Apr; 3¹: 7–11.doi: 10.15420/cfr.2016:25:2 2. Masoudi FA, et al. Arch Intern Med.2005;165(18):2069-2076.
6. Masoudi FA, et al. Arch Intern Med.2005;165(18):2069-2076.
7. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, Theresa AMcDonagh & al, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726 4. A. E. Bagriy, et al. 2014 Adv Ther DOI 10.1007/s12325-015-0185-5 5. Bocchi, E.A., et al., The SHIFT Carvedilol Subanalysis. Cardiology, 2015. 131⁴: p. 218-24. 6. Komajda, M., et al., QUALIFY international registry. Eur J Heart Fail, 2017. 19(11): p. 1414-1423.
Keep up to date with our content
Subscribe to our newsletter so that you are always up to date with the news.